Gaja Shaughnessy
Sleep Medicine · Naples, FLNPI 1720422314
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 26.5% of the total. Reporting peaked in 2023 at $1,334 and has fallen 67.5% since, to $434 in 2025.
Across 54 payments — averaging $50.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$717
- GSK$452
- AstraZeneca$308
- Insmed, Inc.$176
- Harmony Biosciences LLC$125
- Jazz Pharmaceuticals Inc.$123
- plus $809 from 15 others
What the payments were for
- Food & beverage$2,711100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 7 | $717 |
| GSK | 8 | $452 |
| AstraZeneca | 8 | $308 |
| Insmed, Inc. | 4 | $176 |
| Harmony Biosciences LLC | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $123 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $121 |
| Lilly USA, LLC | 1 | $110 |
| Sanofi | 3 | $90 |
| Regeneron Healthcare Solutions, Inc. | 2 | $69 |
| Baxter Healthcare | 3 | $69 |
| Paratek Pharmaceuticals, Inc. | 3 | $68 |
| Merck | 2 | $48 |
| Grifols USA, LLC | 2 | $46 |
| Inogen, Inc. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Medtronic | 1 | $27 |
| Boehringer Ingelheim | 1 | $24 |
| Philips North America LLC | 1 | $18 |
| Vapotherm Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,711 in reported general payments places this provider in the 55th percentile of 77 sleep medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $132,428 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $32,509 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $30,577 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $20,040 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $15,934 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $11,497 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $7,458 |
| Arnuity ElliptaFluticasone Furoate | 18 | $6,603 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 122 | $3,338 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,966 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,062 |
| Ventolin HfaAlbuterol Sulfate | 29 | $1,445 |
| Azelastine Hcl | 34 | $700 |
| Ipratropium Bromide | 15 | $442 |
| Montelukast Sodium | 43 | $422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $452 | $189,647210 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $308 | $44,00775 claims |
| Boehringer IngelheimStiolto Respimat | $24 | $15,93422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 77 sleep medicine providers in Florida.
Other sleep medicine in Naples
- Blirjon BaxhijaNaples$1K
- Jeremy McConnellBradenton$615K
- Edward MezerhaneMiami$537K
- Shane DrahosWinter Garden$317K
- Kunal AgarwalSarasota$153K
- Camilo RuizFort Lauderdale$136K
- Sergio JaramilloMiami$32K
- Carlos Ramirez MejiaMiami$25K
- Luis OrtizSt Petersburg$24K
- Harneet WaliaMiami$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.